Celastrol, a Triterpene Extracted from the Chinese “Thunder of God Vine,” Is a Potent Proteasome Inhibitor and Suppresses Human Prostate Cancer Growth in Nude Mice
Top Cited Papers
- 1 May 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 66 (9) , 4758-4765
- https://doi.org/10.1158/0008-5472.can-05-4529
Abstract
Interest in the use of traditional medicines for cancer prevention and treatment is increasing. In vitro, in vivo, and clinical studies suggest the potential use of proteasome inhibitors as novel anticancer drugs. Celastrol, an active compound extracted from the root bark of the Chinese medicine “Thunder of God Vine” (Tripterygium wilfordii Hook F.), was used for years as a natural remedy for inflammatory conditions. Although Celastrol has been shown to induce leukemia cell apoptosis, the molecular target involved has not been identified. Furthermore, whether Celastrol has antitumor activity in vivo has never been conclusively shown. Here, we report, for the first time, that Celastrol potently and preferentially inhibits the chymotrypsin-like activity of a purified 20S proteasome (IC50 = 2.5 μmol/L) and human prostate cancer cellular 26S proteasome (at 1-5 μmol/L). Inhibition of the proteasome activity by Celastrol in PC-3 (androgen receptor- or AR-negative) or LNCaP (AR-positive) cells results in the accumulation of ubiquitinated proteins and three natural proteasome substrates (IκB-α, Bax, and p27), accompanied by suppression of AR protein expression (in LNCaP cells) and induction of apoptosis. Treatment of PC-3 tumor–bearing nude mice with Celastrol (1-3 mg/kg/d, i.p., 1-31 days) resulted in significant inhibition (65-93%) of the tumor growth. Multiple assays using the animal tumor tissue samples from both early and end time points showed in vivo inhibition of the proteasomal activity and induction of apoptosis after Celastrol treatment. Our results show that Celastrol is a natural proteasome inhibitor that has a great potential for cancer prevention and treatment. (Cancer Res 2006; 66(9): 4758-65)Keywords
This publication has 34 references indexed in Scilit:
- Novel Mechanism of Inhibition of Nuclear Factor-κB DNA-Binding Activity by Diterpenoids Isolated from Isodon rubescensMolecular Pharmacology, 2005
- Celastrol inhibits pro-inflammatory cytokine secretion in Crohn’s disease biopsiesPublished by Elsevier ,2004
- Antitumor Agents. 228. Five New Agarofurans, Reissantins A−E, and Cytotoxic Principles from Reissantia buchananiiJournal of Natural Products, 2003
- Observation on serum anti-double stranded DNA antibodies of tripterine in systemic lupus erythematosus of (NZB×W)F1 miceAnnals of the Rheumatic Diseases, 2003
- New TNF-α releasing inhibitors as cancer preventive agents from traditional herbal medicine and combination cancer prevention study with EGCG and sulindac or tamoxifenMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2003
- Selective accumulation of CCR4+ T lymphocytes into renal tissue of patients with lupus nephritisArthritis & Rheumatism, 2002
- The Bcl-2 Protein Family: Arbiters of Cell SurvivalScience, 1998
- Mitochondria and ApoptosisScience, 1998
- Basic science aspects of prostate cancerSeminars in Cancer Biology, 1997
- Role of the Ubiquitin-Proteasome Pathway in Regulating Abundance of the Cyclin-Dependent Kinase Inhibitor p27Science, 1995